Empirical Pharmacokinetic/Pharmacodynamic Models

Pharmacometrics: The Science of Quantitative Pharmacology

Volumn , Issue , 2006, Pages 529-545

  Uchizono, James A ^a   Lane, James R ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Chronopharmacokinetics; Direct empirical models; Drug tolerance; Emax model; Linear pharmacodynamic model; Pharmacokinetic pharmacodynamic modeling; Sigmoidal Emax model; Splines; The link model; Time invariant systems; Time variant systems

Indexed keywords

EID: 60349097109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470087978.ch20     Document Type: Chapter

References (71)

1. T. Teorell, Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn 57:205-225 (1937).
2. T. Teorell, Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration. Arch Int Pharmacodyn 57:226-240 (1937).
3. G. E. P. Box and N. R. Draper, Empirical Model-Building and Response Surfaces. Wiley, Hoboken, NJ, 1987, pp. 1-3, 15-33.
4. P. Bonate, W. R. Gillespie, T. Ludden, D. B. Rubin, and D. Stanski, Simulation in Drug Development: Good Practices, Version 1.0. Draft Publication of the Center for Drug Development Science (CDDS), 1999, pp. 1-19.
5. R. F. Furchgott, The pharmacology of vascular smooth muscle. Pharmacol Rev 7:183-265 (1955).
6. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham, Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371 (1979).
7. G. Segre, Kinetics of interaction between drugs and biological systems. Farmaco (Sci) 23:907-918 (1968).
8. W. A. Colburn, Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm 9:367-388 (1981).
9. W. A. Colburn, Combined pharmacokinetic/pharmacodynamic (PK/PD) modeling. J Clin Pharmacol 28:769-771 (1988).
10. C. Csajka and D. Verotta, Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 1-53 (2006).
11. M. Danhof, Applications of pharmacokinetic/pharmacodynamic research in rational drug development. Methods Find Exp Clin Pharmacol 18 (Suppl C):53-54 (1996).
12. M. Danhof, J. W. Mandema, A. Hoogerkamp, and R. A. Mathot, Pharmacokinetic- pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Eur J Drug Metab Pharmacokinet 18:41-47 (1993).
13. H. Derendorf, L. J. Lesko, P. Chaikin, W. A. Colburn, P. Lee, R. Miller, R. Powell, G. Rhodes, D. Stanski, and J. Venitz, Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 40:1399-1418 (2000).
14. N. H. G. Holford and L. B. Sheiner, Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453 (1981).
15. J. D. Unadkat, F. Bartha, and L. B. Sheiner, Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 40:86-93 (1986).
16. J. G. Wagner, Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20:173-201 (1968).
17. R. L. Galeazzi, L. Z. Benet, and L. B. Sheiner, Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 20:278-289 (1976).
18. I. S. Nestorov, S. T. Hadjitodorov, I. Petrov, and M. Rowland, Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates. AAPS Pharm Sci 1:E17 (1999).
19. W. J. Jusko, H. C. Ko, and W. F. Ebling, Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 23:5-8; discussion 9-10 (1995).
20. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd ed. Drugs and the Pharmaceutical Sciences, Vol. 15. Marcel Dekker, New York, 1982, pp. 45-144.
21. M. Rowland, in Pharmacokinetics, A Modern View, L. Z. Benet, G. Levy, and B. L. Ferraiolo (Eds). Plenum Press, New York, 1984, pp. 133-146.
22. M. Rowland and T. N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Williams & Wilkins, Baltimore, 1995, pp. 137-152.
23. J. W. Mandema, C. D. Heijligers-Feijen, E. Tukker, A. G. De Boer, and M. Danhof, Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures. J Pharmacol Exp Ther 261:88-95 (1992).
24. P. Veng-Pedersen, J. W. Mandema, and M. Danhof, Biophase equilibration times. J Pharm Sci 80:881-886 (1991).
25. P. Veng-Pedersen and N. B. Modi, Pharmacodynamic system analysis of the biophase level predictor and the transduction function. J Pharm Sci 81:925-934 (1992).
26. B. E. Dahlstrom, L. K. Paalzow, G. Segre, and A. J. Agren, Relation between morphine pharmacokinetics and analgesia. J Pharmacokinet Biopharm 6:41-53 (1978).
27. F. D. Boudinot, R. D'Ambrosio, and W. J. Jusko, Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm 14:469-493 (1986).
28. M. L. Jack, W. A. Colburn, N. M. Spirt, G. Bautz, M. Zanko, W. D. Horst, and R. A. O'Brien, A pharmacokinetic/pharmacodynamic/receptor binding model to predict the onset and duration of pharmacological activity of the benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 7:629-635 (1983).
29. T. P. Kenakin, Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed. Lippincott-Raven Publishers, Philadelphia, 1997, pp. 11-26.
30. D. A. Lauffenburger and J. J. Linderman, Receptors: Models for Binding, Trafficking, and Signaling. Oxford University Press, New York, 1993, pp. 135-281.
31. L. D. Limbird, Cell Surface Receptors: A Short Course on Theory and Methods, 2nd ed. Kluwer Academic Publishers, Boston, 1996, pp. 27-60.
32. N. L. Dayneka, V. Garg, and W. J. Jusko, Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478 (1993).
33. M. Danhof, G. Alvan, S. G. Dahl, J. Kuhlmann, and G. Paintaud, Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22:1432-1437 (2005).
34. D. E. Mager and W. J. Jusko, Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216 (2001).
35. Y. N. Sun and W. J. Jusko, Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732-737 (1998).
36. G. Levy, Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J Pharm Sci 53:342-343 (1964).
37. G. Levy, Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362-372 (1966).
38. E. J. Arièens, Molecular Pharmacology: The Mode of Action of Biologically Active Compounds. Academic Press, New York, 1964, pp. 29-42.
39. S. Dutta, Y. Matsumoto, and W. F. Ebling, Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci 85:232-239 (1996).
40. B. Alexander, D. J. Browse, S. J. Reading, and I. S. Benjamin, A simple and accurate mathematical method for calculation of the EC50. J Pharmacol Toxicol Methods 41:55-58 (1999).
41. F. Patron-Bizet, F. Mentre, M. Genton, C. Thomas-Haimez, and J. Maccario, Assessment of the global two-stage method to EC50 determination. J Pharmacol Toxicol Methods 39:103-108 (1998).
42. P. H. Van der Graaf and R. C. Schoemaker, Analysis of asymmetry of agonist concentration-effect curves. J Pharmacol Toxicol Methods 41:107-115 (1999).
43. L. Aarons, C. Baxter, and S. Gupta, Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions. Biopharm Drug Dispos 25:219-225 (2004).
44. L. Li, M. B. Brown, K. H. Lee, and S. Gupta, Estimation and inference for a splineenhanced population pharmacokinetic model. Biometrics 58:601-611 (2002).
45. K. Park, D. Verotta, T. F. Blaschke, and L. B. Sheiner, A semiparametric method for describing noisy population pharmacokinetic data. J Pharmacokinet Biopharm 25:615-642 (1997).
46. D. Verotta, Volterra series in pharmacokinetics and pharmacodynamics. J Pharmacokinet Pharmacodyn 30:337-362 (2003).
47. R. H. Bartels, J. C. Beatty, and B. A. Barsky, An Introduction to Splines for Use in Computer Graphics and Geometric Modeling. Morgan Kaufmann Publishers, Los Altos, CA, 1987, pp. 9-17.
48. R. L. Burden, Numerical Analysis, 8th ed. Brooks/Cole, Belmont, CA, 2005, pp. 137-156.
49. W. H. Press, S. A. Teukolsky, W. T. Vetterling, and B. P. Flannery, Numerical Recipes in C: The Art of Scientific Computing, 2nd ed. Cambridge University Press, New York, 1992, pp. 113-116.
50. D. Verotta and L. B. Sheiner, Semiparametric analysis of non-steady-state pharmacodynamic data. J Pharmacokinet Biopharm 19:691-712 (1991).
51. B. Lemmer and B. Bruguerolle, Chronopharmacokinetics. Are they clinically relevant? Clin Pharmacokinet 26:419-427 (1994).
52. F. Levi, Circadian chronotherapy for human cancers. Lancet Oncol 2:307-315 (2001).
53. B. Bruguerolle, Chronopharmacokinetics. Current status. Clin Pharmacokinet 35:83-94 (1998).
54. R. C. Hermida and M. H. Smolensky, Chronotherapy of hypertension. Curr Opin Nephrol Hypertens 13:501-505 (2004).
55. B. E. Harris, R. Song, S. J. Soong, and R. B. Diasio, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201 (1990).
56. G. Metzger, C. Massari, M. C. Etienne, M. Comisso, S. Brienza, Y. Touitou, G. Milano, G. Bastian, J. L. Misset, and F. Levi, Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther 56:190-201 (1994).
57. E. Petit, G. Milano, F. Levi, A. Thyss, F. Bailleul, and M. Schneider, Circadian rhythmvarying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48:1676-1679 (1988).
58. F. Levi, R. Zidani, and J. L. Misset, Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350:681-686 (1997).
59. G. Milano and A. L. Chamorey, Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177-189 (2002).
60. F. Bressolle, J. M. Joulia, F. Pinguet, M. Ychou, C. Astre, J. Duffour, and R. Gomeni, Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 44:295-302 (1999).
61. H. C. Porchet, N. L. Benowitz, and L. B. Sheiner, Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 244:231-236 (1988).
62. L. B. Sheiner, Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther 46:605-615 (1989).
63. J. Shi, N. L. Benowitz, C. P. Denaro, and L. B. Sheiner, Pharmacokinetic- pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 53:6-14 (1993).
64. D. M.-C. Ouellet and G. M. Pollack, Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats. J Pharmacol Exp Ther 281:713-720 (1997).
65. H. P. Rang and J. M. Ritter, On the mechanism of desensitization at cholinergic receptors. Mol Pharmacol 6:357-382 (1970).
66. B. Katz and S. Thesleff, A study of the "Desensitization" produced by acetylcholine at motor end-plate. J Physiol 138:63-80 (1957).
67. G. Weiland, B. Georgia, S. Lappi, C. F. Chignell, and P. Taylor, Kinetics of agonistmediated transitions in state of the cholinergic receptor. J Biol Chem 252:7648-7656 (1977).
68. L. A. Segel, A. Goldbeter, P. N. Devreotes, and B. E. Knox, A mechanism for exact sensory adaptation based on receptor modification. J Theor Biol 120:151-179 (1986).
69. V. Licko, Drugs, receptors and tolerance, in Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs, G. Barnett and C. N. Chary (Ed.). Biomedical Publications, Foster City, 1985, pp. 311-322.
70. A. Sharma, W. F. Ebling, and W. J. Jusko, Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584 (1998).
71. M. Gardmark, L. Brynne, M. Hammarlund-Udenaes, and M. O. Karlsson, Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 36:145-167 (1999).